To The Main Page
About RTC Our Projects Stem Cell Therapy Research Translation Service/Technology Transfer Contact

Joint project with the
Polyclinic for dental preservation & periodontology

"Cardiovascular programming of human, dental, follicular stem cells"

Project Manager   Prof. Dr. med. Robert David, Prof. Dr. med. Hermann Lang

 

 


 

01. Sep. 2016 -
Dec. 31, 2019

Project number
F 2016/11
promoted by
Damp Foundation

Joint project iRhythmics
our subproject
"Forward programming of pacemaker cells and development of an organoid's cardiac conduction"

Joint and sub-project leader Prof. Dr. med. Robert David

 


 

01. Oct. 2018 -
30th Sep 2021
Project number
ESF/14-BM-A55-0024/18
funded by
LaGuS M / V, ESF

Community project with the
Institute for Experimental Gene Therapy and Tumor Research
"Development & Application of Optimized Cardiospecific AdVector-Based Systems for In Situ Establishment of a Biological Pacemaker"

Project Manager Prof. Dr. med. Robert David, Prof. Dr. med. Brigitte M. Pützer


 

01. Oct. 2018 -
30th Sep 2020

Project number
DA 1296 / 6-1

funded by DFG

Joint project
"programmed sinus node tissue for therapy and test systems - iSAB"

our subproject
"stem cell-activated pacemaker cells for in vivo and in vitro use"

Project leader:  Prof. dr. Gustav Steinhoff, Prof. dr. Robert David


 

01. May 2016 -
Dec. 31, 2019

Project number
03 VP 00 241

funded by BMBF

Joint research project „Added value in regenerative medicine – a pioneering approach to facilitate translation“

The foundation of the RTC is based on the joint research project “Added value in regenerative medicine”which is funded for four years. It has two goals:

1) Fostering the continued development of cardiac stem cell therapies so that they can be applied as standardised treatments of high quality to patients showing appropriate indications. This requires proof of efficacy and safety of the therapy in accordance with all relevant regulations and guidelines by means of clinical studies and parallel research projects.

2) Standardisation of the translational process. According to the latest legal situation, treatments with stem cells belong to the “Advanced Therapy Medicinal Product ”. The essential transfer process from basic research to the launch of stem cell therapy as a novel drug or treatment method ( translation) is virgin territory for scientists, as well as industry and licensing authorities. Using the example of cardiac stem cell therapy, the RTC will work closely with all relevant authorities to define standards which offer a maximun of quality and safety for patients. In addition, information regarding the translational process will be made available (link zu Translation). Further research and development projects in the field of regenerative medicine will directly benefit from the accumulated know-how and technologies. The RTC will offer trainings and seminars for prospective users of the standardised stem cell therapies.

 

 

Legal The RTC is supported by the BMBF and the State Mecklenburg-Western Pomerania using EU Structural Funds.